Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2023-06-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
独立董事关于公司2023年度以简易程序向特定对象发行股票相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent directors' opinion on the company's 2023 simplified procedure private placement of shares. It discusses compliance with laws and regulations, the issuance plan, feasibility, use of funds, and shareholder return plans. It is a formal opinion related to a specific capital raising event but does not itself announce the capital raising or provide financial results. The document is relatively short (2150 characters) and focuses on the independent directors' review and approval of the issuance plan and related matters. This fits best under Capital/Financing Update (CAP) as it relates to a specific financing activity (private placement of shares) and the independent directors' opinions on it. It is not a full financial report, earnings release, or regulatory filing. Therefore, the classification is CAP with high confidence.
2023-06-27 Chinese
关于第五届董事会第十一次会议决议的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 11th meeting of the 5th Board of Directors of 特一药业集团股份有限公司 on June 27, 2023. It includes multiple board decisions related to a simplified procedure for issuing shares to specific targets, including approval of the issuance plan, pricing, quantity, use of proceeds, and related reports. The document also mentions the convening of an extraordinary general meeting to approve these matters. The content focuses on board-level decisions and approvals rather than the full issuance report or financial statements. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement. The document is a formal board meeting resolution announcement concerning capital raising activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5432 characters) and detailed content support this classification with high confidence.
2023-06-27 Chinese
非经常性损益审核报告
Regulatory Filings
2023-06-27 Chinese
章程修正案
Share Issue/Capital Change Classification · 95% confidence The document is a company announcement regarding amendments to the company's articles of association due to changes in registered capital and total shares following convertible bond conversions, equity incentives, and equity distribution. It mentions that the amendments do not require further shareholder approval as they were authorized by the 2022 annual general meeting and need to be filed with the market supervision authority. The document is short (608 characters) and focuses on capital changes and related amendments to the articles of association, not a full report or financial statements. This fits the category of Share Issue/Capital Change (SHA) rather than an annual report or governance report. It is not a report publication announcement or regulatory filing as it contains substantive content about capital changes and articles amendment.
2023-06-27 Chinese
特一药业2023年度以简易程序向特定对象发行股票的预案
Capital/Financing Update Classification · 100% confidence The document is a detailed plan (预案) for a 2023 simplified procedure private placement of shares by Teyi Pharmaceutical Group Co., Ltd. It includes extensive information about the issuance background, purpose, target investors, pricing, number of shares, use of proceeds, approvals, and risk disclosures. The document is lengthy (15,000 characters) and contains substantive content about the capital raising plan, including financial and strategic details. It is not a brief announcement or a certification but a comprehensive proposal related to a capital raising activity. Therefore, it fits the category of a Capital/Financing Update (CAP).
2023-06-27 Chinese
关于2023年度以简易程序向特定对象发行股票摊薄即期回报及填补措施和相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 特一药业集团股份有限公司 regarding a 2023 annual issuance of shares to specific investors using a simplified procedure. It discusses the dilution of immediate returns, risk warnings, financial impact analysis on earnings per share and return on equity, and measures to compensate for dilution. It includes commitments from the board, senior management, and controlling shareholders to ensure the fulfillment of these measures. The document references regulatory guidelines from Chinese authorities such as the China Securities Regulatory Commission and Shenzhen Stock Exchange. The content focuses on the capital raising event, its financial impact, and related commitments rather than presenting a full financial report or earnings release. The document length is 7602 characters, which is substantial and contains detailed financial impact analysis and company commitments. This fits the category of a Capital/Financing Update (CAP) as it provides detailed information about a specific financing activity (stock issuance), its impact, and related governance measures. It is not an earnings release, annual report, or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2023-06-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.